Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes

Launched by CHILDREN'S HOSPITAL OF FUDAN UNIVERSITY · May 2, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at how a medication called cyclophosphamide can help patients who have both acquired lipodystrophy syndrome and type 1 diabetes. Lipodystrophy is a condition where the body does not have enough fat, which can lead to problems with how the body uses insulin and manages blood sugar. The goal of this study is to see if treatment with cyclophosphamide can improve insulin resistance and help with glucose metabolism in these patients.

To participate in this trial, individuals must have been diagnosed with type 1 diabetes and show signs of panniculitis, which is an inflammation of fat tissue. They should also meet specific criteria for lipodystrophy, such as having low levels of a hormone called leptin and having no genetic causes for their condition. However, people with other serious health issues, active infections, or certain cancers will not be eligible to join. Participants can expect to be closely monitored during the trial to assess how the treatment affects their diabetes and overall health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Meet the diagnostic criteria of type 1 diabetes mellitus: clinical manifestations of typical diabetes mellitus include polyphagia, polyuria, weight loss, or diabetic ketoacidosis, confirmed by blood sugar level, islet function and autoimmune antibody.
• • 2. Meet the diagnostic criteria for panniculitis: fat biopsy suggests inflammatory infiltration.
• • 3. Meet the diagnostic criteria for acquired lipodystrophy syndrome: childhood onset, clinically no nutritional deficiency or catabolism, systemic or partial subcutaneous fat reduction, genetic testing to exclude congenital lipodystrophy syndrome; low leptin level and autoantibodies can aid in diagnosis.
• Exclusion Criteria:
• • 1. Mature and effective treatment methods are available.
• • 2. HIV, HBV and HCV were positive.
• • 3. A the active period of infection.
• • 4. At the active stage of malignant tumors.
• • 5. Combination of other fatal diseases.
• • 6. Existence of mental and psychological diseases.